Related Experiment Video

Updated: Aug 21, 2026

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
05:52

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

Update on childhood neutropenia: molecular and clinical advances

Yigal Dror1, Lillian Sung

  • 1Division of Hematology/Oncology, The Hospital for Sick Children and The University of Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada. yigal.dror@sickkids.ca

Hematology/Oncology Clinics of North America
|October 30, 2004
PubMed

Insights

Inherited neutropenias are crucial diagnoses in children, distinct from more common acquired forms. Recent research advances our understanding of their cellular defects, clinical features, and management strategies.

Area of Science:

  • Pediatric Hematology
  • Genetics
  • Immunology

Background:

  • Neutropenia is a condition characterized by an abnormally low level of neutrophils.
  • While acquired causes are more frequent, congenital and inherited disorders are significant differential diagnoses, especially in pediatric populations.
  • Understanding the genetic basis of inherited neutropenias is critical for accurate diagnosis and management.

Purpose of the Study:

  • To review recent advancements in the understanding of inherited neutropenias.
  • To discuss the cellular and molecular defects underlying these conditions.
  • To highlight clinical presentation, diagnostic approaches, and potential complications.

Main Methods:

  • Literature review of recent research on inherited neutropenias.
  • Analysis of cellular and molecular mechanisms.
  • Synthesis of clinical data regarding presentation, diagnosis, and complications.

Main Results:

  • Recent studies have elucidated specific cellular and molecular defects in various inherited neutropenias.
  • Advances in genetic analysis have improved diagnostic capabilities.
  • A better understanding of complications associated with these disorders has emerged.

Conclusions:

  • Inherited neutropenias represent a distinct group of disorders with specific genetic underpinnings.
  • Continued research is vital for improving the diagnosis and clinical management of pediatric neutropenia.
  • Focusing on genetic defects aids in personalized treatment approaches.

More Related Videos

ATAC-Seq Library Preparation of Murine Bone Marrow-Derived Neutrophils09:44

ATAC-Seq Library Preparation of Murine Bone Marrow-Derived Neutrophils

Published on: January 3, 2025

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...